MedDataX Logo

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

NCT ID: NCT00320398

Last Updated: 2018-09-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-30

Study Completion Date

2006-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

NCT00320424

Thromboembolism
COMPLETED PHASE3

Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

NCT00333021

Venous Thromboembolism
COMPLETED PHASE3

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.

NCT00555438

Major Orthopaedic Surgery and Renal Impairment
COMPLETED PHASE4

Dose Ranging Study in Elective Total Hip Replacement Surgery

NCT00338897

Venous Thromboembolism
COMPLETED PHASE2/PHASE3

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

NCT00911157

Thrombosis, Venous
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombosis, Venous

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fondaparinux

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing either an elective primary THR (total hip replacement) surgery or a revision of a THR.

Exclusion Criteria

* Active, clinically significant bleeding (excluding drainage).
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

, ,

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AR3106333

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
NCT00423319 COMPLETED PHASE3
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01203098 COMPLETED PHASE2
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
NCT01444612 COMPLETED
The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
NCT00981409 COMPLETED PHASE3
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
NCT00398216 COMPLETED PHASE2
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
NCT00697099 COMPLETED PHASE3
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
NCT00306254 COMPLETED PHASE2
Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)
NCT00541320 WITHDRAWN PHASE2
Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery
NCT00767559 UNKNOWN NA
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
NCT01420809 COMPLETED
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
NCT00789399 TERMINATED NA
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
NCT00531843 COMPLETED PHASE2/PHASE3
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
NCT00349180 COMPLETED PHASE3
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01181167 COMPLETED PHASE3
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
NCT00074828 COMPLETED PHASE2
SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
NCT05752461 COMPLETED PHASE2
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
NCT00168818 COMPLETED PHASE3
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery
NCT01390896 COMPLETED
Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA
NCT01139658 COMPLETED
Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
NCT01809054 COMPLETED PHASE4
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
NCT00413504 COMPLETED NA
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
NCT00331838 COMPLETED PHASE2
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
NCT01857583 COMPLETED PHASE3
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
NCT00843492 COMPLETED PHASE3
Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
NCT00436787 COMPLETED PHASE2